Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (88)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pozzo, C.
Right arrow Articles by Barone, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pozzo, C.
Right arrow Articles by Barone, C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:933-939, 2004
© 2004 European Society for Medical Oncology


Original Paper

Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients

Received 25 September 2003; revised 28 January 2004; accepted 2 February 2004

Background:

The aim of this study was to observe the effects of neoadjuvant therapy with irinotecan and 5-fluorouracil (5-FU)/folinic acid (FA) on the resection rate and survival of colorectal cancer patients with initially unresectable hepatic metastases.

Patients and methods:

Forty patients received neoadjuvant chemotherapy comprising irinotecan 180 mg/m2 administered intravenously (i.v.) on day 1, FA 200 mg/m2 i.v. on days 1 and 2, 5-FU 400 mg/m2 i.v. bolus on days 1 and 2, and 5-FU 1200 mg/m2 as a continuous 48-h i.v. infusion on day 1. The treatment was repeated every 2 weeks and response was assessed every 12 weeks (six cycles).

Results:

The objective response rate to chemotherapy was 47.5% (n = 19), with two complete responses and disease stabilization in 11 (27.5.%) patients. Responses were unconfirmed for 11 patients undergoing surgery within 2 weeks. Treatment was well tolerated and adverse events were typical of the chemotherapy agents used. Twenty-seven (67.5%) patients reported hematological toxicity (35.0% grade 3/4) and 14 (35.0%) reported gastrointestinal toxicity (12.5% grade 3/4). Thirteen patients (32.5%) underwent potentially curative liver resection following chemotherapy. Chemotherapy was particularly effective in patients with large metastases on entry to the study. The median time to progression is 14.3 months and, at a median follow-up of 19 months, all patients are alive.

Conclusions:

Neoadjuvant therapy with irinotecan combined with 5-FU/FA enabled a significant proportion of patients with initially unresectable liver metastases to undergo surgical resection. The effects of treatment on survival have yet to be determined.

C. Pozzo1, M. Basso1, A. Cassano1, M. Quirino1, G. Schinzari1, N. Trigila1, M. Vellone2, F. Giuliante2, G. Nuzzo2 and C. Barone1,*

1 Unit of Medical Oncology, Department of Internal Medicine and 2 Unit of Hepatobiliary Surgery, Department of General Surgery, Catholic University of Sacred Heart, Rome, Italy

Key words: colorectal, 5-fluorouracil, irinotecan, liver, neoadjuvant, unresectable


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Jpn J Clin OncolHome page
R. Zhao, J. Zhu, X. Ji, J. Cai, F. Wan, Q. Li, B. Zhong, S. Tucker, and D. Wang
A Phase II Study of Irinotecan and Capecitabine for Patients with Unresectable Liver-only Metastases from Colorectal Cancer
Jpn. J. Clin. Oncol., January 1, 2010; 40(1): 10 - 16.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
N. E. Kemeny, F. D. H. Melendez, M. Capanu, P. B. Paty, Y. Fong, L. H. Schwartz, W. R. Jarnagin, D. Patel, and M. D'Angelica
Conversion to Resectability Using Hepatic Artery Infusion Plus Systemic Chemotherapy for the Treatment of Unresectable Liver Metastases From Colorectal Carcinoma
J. Clin. Oncol., July 20, 2009; 27(21): 3465 - 3471.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
B. Nordlinger, E. Van Cutsem, T. Gruenberger, B. Glimelius, G. Poston, P. Rougier, A. Sobrero, M. Ychou, and on behalf of the European Colorectal Metastases Tr
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel
Ann. Onc., June 1, 2009; 20(6): 985 - 992.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
S. R. Alberts and L. D. Wagman
Chemotherapy for Colorectal Cancer Liver Metastases
Oncologist, October 1, 2008; 13(10): 1063 - 1073.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
R. Adam, T. Aloia, F. Levi, D. A. Wicherts, R. J. de Haas, B. Paule, M.-P. Bralet, M. Bouchahda, D. Machover, M. Ducreux, et al.
Hepatic Resection After Rescue Cetuximab Treatment for Colorectal Liver Metastases Previously Refractory to Conventional Systemic Therapy
J. Clin. Oncol., October 10, 2007; 25(29): 4593 - 4602.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Falcone, S. Ricci, I. Brunetti, E. Pfanner, G. Allegrini, C. Barbara, L. Crino, G. Benedetti, W. Evangelista, L. Fanchini, et al.
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
J. Clin. Oncol., May 1, 2007; 25(13): 1670 - 1676.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. Leichman
Neoadjuvant Chemotherapy for Disseminated Colorectal Cancer: Changing the Paradigm
J. Clin. Oncol., August 20, 2006; 24(24): 3817 - 3818.
[Full Text] [PDF]


Home page
JCOHome page
S. Benoist, A. Brouquet, C. Penna, C. Julie, M. El Hajjam, S. Chagnon, E. Mitry, P. Rougier, and B. Nordlinger
Complete Response of Colorectal Liver Metastases After Chemotherapy: Does It Mean Cure?
J. Clin. Oncol., August 20, 2006; 24(24): 3939 - 3945.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. Poston, R. Adam, and J.-N. Vauthey
Downstaging or Downsizing: Time for a New Staging System in Advanced Colorectal Cancer?
J. Clin. Oncol., June 20, 2006; 24(18): 2702 - 2706.
[Full Text] [PDF]


Home page
JCOHome page
C. Garufi, G. M. Ettorre, B. Vanni, A. Torsello, and E. Terzoli
Neoadjuvant Chemotherapy for Metastatic Colon Cancer: Too Much Caution and Still Too Much to Be Assessed
J. Clin. Oncol., May 10, 2006; 24(14): 2217 - 2218.
[Full Text] [PDF]


Home page
JCOHome page
G. Chong and D. Cunningham
Improving Long-Term Outcomes for Patients With Liver Metastases From Colorectal Cancer
J. Clin. Oncol., December 20, 2005; 23(36): 9063 - 9066.
[Full Text] [PDF]


Home page
JCOHome page
G. J. Poston, R. Adam, S. Alberts, S. Curley, J. Figueras, D. Haller, F. Kunstlinger, G. Mentha, B. Nordlinger, Y. Patt, et al.
OncoSurge: A Strategy for Improving Resectability With Curative Intent in Metastatic Colorectal Cancer
J. Clin. Oncol., October 1, 2005; 23(28): 7125 - 7134.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
G. Folprecht, A. Grothey, S. Alberts, H.-R. Raab, and C.-H. Kohne
Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates
Ann. Onc., August 1, 2005; 16(8): 1311 - 1319.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
N. J. Petrelli, J. Abbruzzese, P. Mansfield, and B. Minsky
Hepatic Resection: The Last Surgical Frontier for Colorectal Cancer
J. Clin. Oncol., July 10, 2005; 23(20): 4475 - 4477.
[Full Text] [PDF]


Home page
JCOHome page
G. D. Leonard, B. Brenner, and N. E. Kemeny
Neoadjuvant Chemotherapy Before Liver Resection for Patients With Unresectable Liver Metastases From Colorectal Carcinoma
J. Clin. Oncol., March 20, 2005; 23(9): 2038 - 2048.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
T. Delaunoit, S. R. Alberts, D. J. Sargent, E. Green, R. M. Goldberg, J. Krook, C. Fuchs, R. K. Ramanathan, S. K. Williamson, R. F. Morton, et al.
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741
Ann. Onc., March 1, 2005; 16(3): 425 - 429.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.